Drawing on over 50 years of drug development experience, Dr. Hausman strengthens the Company’s mission to combat cancer and other serious diseases. ORLANDO, Fla., Dec. 04, 2025 (GLOBE NEWSWIRE) -- LAMY, to become Exousia Bio, Inc. (OTCPINK: LMMY) (the “Company” or “Exo Bio”), operating as a leading U.S. biotechnology company focused on exosome-based cancer therapy, announced the release of a new interview with strategic consultant Dr. Marvin Hausman, an esteemed Immunologist and Board-Certified Urological S ...

Core Insights - Pluri Inc. has launched a wholly-owned subsidiary, Cellav Health and Aesthetics Ltd., focusing on regenerative solutions using its proprietary 3D cell expansion platform [1][6] - Cellav has secured a commercial collaboration with Miss Universe Skincare to co-develop a new line of advanced, cell-based skincare products [1][2] - The first product from this collaboration is expected to launch in the first half of 2026, leveraging Miss Universe Skincare's global distribution platform [2][6] Company Overview - Cellav aims to transform cutting-edge cell science into impactful solutions for health and aesthetics, bridging science with real-world results [5][7] - The subsidiary will operate in three core areas: developing premium cell-derived ingredients, offering professional-use and consumer-ready products, and providing a flexible technology platform for partners [7] - Cellav's offerings are backed by over two decades of Pluri's expertise in pharmaceutical-grade development [7] Market Potential - The beauty market, where Cellav is expanding, is projected to reach $194.05 billion by 2032, indicating significant growth opportunities [6] - The collaboration with Miss Universe Skincare is seen as a strategic move to tap into high-growth, revenue-generating markets [2][4] Leadership and Vision - Cellav is led by CEO Katty Dowery, who has extensive experience in cell-based technologies and regenerative medicine [3][4] - The company emphasizes scientific integrity and high-quality standards, aiming to make regenerative science accessible and impactful in the beauty industry [4][5]

Core Insights - Adia Nutrition Inc. reported a remarkable revenue increase of over 100% in the third quarter compared to the previous quarter, alongside a profit margin exceeding 20%, highlighting its strong position in the regenerative medicine industry driven by high demand for its therapies [1][6]. Financial Performance - Revenue surged by more than 100% from the second quarter, primarily due to increased sales of umbilical cord stem cells and exosomes through various channels including clinical partnerships and direct-to-consumer sales [6]. - The company achieved a profit margin exceeding 20%, reflecting operational efficiency and the success of its high-margin therapeutic offerings [6]. Strategic Positioning - The third quarter results signify a historic leap for Adia Nutrition, showcasing the company's commitment to redefining possibilities in the regenerative medicine sector [2]. - The company is positioned for record-breaking annual growth and enhanced shareholder value, building on its year-to-date success [6]. Business Model and Offerings - Adia Nutrition operates two main divisions: a supplement division focused on premium organic supplements and a medical division that specializes in advanced stem cell therapies, including Umbilical Cord Stem Cells and Autologous Hematopoietic Stem Cell Transplantation [5]. - The company is actively seeking strategic partnerships to expand access to its regenerative therapies [4].